Joseph E. Payne

Discovery of Inducible Nitric Oxide Synthase (iNOS) Inhibitor Development Candidate KD7332, Part 1: Identification of a Novel, Potent, and Selective Series of Quinolinone iNOS Dimerization Inhibitors that are Orally Active in Rodent Pain Models

Céline Bonnefous, Joseph E. Payne, Jeffrey Roppe et al. · Journal of Medicinal Chemistry · 2009 · 69 citations · Full text

Pharmacy, Medicinal Chemistry, Pharmacology +13

Discovery of Dual Inducible/Neuronal Nitric Oxide Synthase (iNOS/nNOS) Inhibitor Development Candidate 4-((2-Cyclobutyl-1<i>H</i>-imidazo[4,5-<i>b</i>]pyrazin-1-yl)methyl)-7,8-difluoroquinolin-2(1<i>H</i>)-one (KD7332) Part 2: Identification of a Novel, Potent, and Selective Series of Benzimidazole-Quinolinone iNOS/nNOS Dimerization Inhibitors That Are Orally Active in Pain Models

Joseph E. Payne, Céline Bonnefous, Kent T. Symons et al. · Journal of Medicinal Chemistry · 2010 · 58 citations · Full text

Medicine, Medicinal Chemistry, Pharmacology +12

KD5170, a novel mercaptoketone-based histone deacetylase inhibitor, exerts antimyeloma effects by DNA damage and mitochondrial signaling

Rentian Feng, Huihui Ma, Christian A. Hassig et al. · Molecular Cancer Therapeutics · 2008 · 51 citations

Life Sciences, Molecular Biology, Oncology +15

KD5170, a novel mercaptoketone-based histone deacetylase inhibitor that exhibits broad spectrum antitumor activity <i>in vitro</i> and <i>in vivo</i>

Christian A. Hassig, Kent T. Symons, Xin Guo et al. · Molecular Cancer Therapeutics · 2008 · 43 citations

Medicine, Oncology, Pharmacology +14

Immune modulatory nanoparticle therapeutics for intracerebral glioma

Nasser K. Yaghi, Jun Wei, Yuuri Hashimoto et al. · Neuro-Oncology · 2016 · 40 citations · Full text

Pharmacy, Immunology, Oncology +17